TY - JOUR
T1 - Feasibility of improving patient's safety with in vivo dose tracking in intracavitary and interstitial HDR brachytherapy
AU - Muenkel, Jessica
AU - Xu, Zhengzheng
AU - Traughber, Bryan J.
AU - Baig, Tanvir
AU - Xu, Keying
AU - Langmack, Christian
AU - Harris, Eleanor
AU - Podder, Tarun K.
N1 - Funding Information:
We would like to thank Bret Boudousquie of RadiaDyne for providing us with extra PSD sensors and solid water phantom that were used for our phantom measurements.
Publisher Copyright:
© 2020 American Brachytherapy Society
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - Purpose: The in vivo dosimetric monitoring in HDR brachytherapy is important for improving patient safety. However, there are very limited options available for clinical application. In this study, we present a new in vivo dose measurement system with a plastic scintillating detector (PSD) for GYN HDR brachytherapy. Methods: An FDA approved PSD system, called OARtrac (AngioDynamics, Latham, NY), was used with various applicators for in vivo dose measurements for GYN patients. An institutional workflow was established for the clinical implementation of the dosimetric system. Action levels were proposed based on the measurement and system uncertainty for measurement deviations. From October 2018 to September 2019, a total of 75 measurements (48 fractions) were acquired from 14 patients who underwent HDR brachytherapy using either a multichannel cylinder, Venezia applicator, or Syed-Neblett template. The PSDs were placed in predetermined catheters/channels. A planning CT was acquired for treatment planning in Oncentra (Elekta, Version-4.5.2) TPS. The PSDs were contoured on the CT images, and the PSD D90% values were used as the expected doses for comparison with the measured doses. Results: The mean difference from patient measurements was −0.22% ± 5.98%, with 26% being the largest deviation from the expected value (Syed case). Large deviations were observed when detectors were placed in the area where dose rates were less than 1 cGy/s. Conclusions: The establishment of clinical workflow for the in vivo dosimetry for both the intracavitary and interstitial GYN HDR brachytherapy will potentially improve the safety of the patient treatment.
AB - Purpose: The in vivo dosimetric monitoring in HDR brachytherapy is important for improving patient safety. However, there are very limited options available for clinical application. In this study, we present a new in vivo dose measurement system with a plastic scintillating detector (PSD) for GYN HDR brachytherapy. Methods: An FDA approved PSD system, called OARtrac (AngioDynamics, Latham, NY), was used with various applicators for in vivo dose measurements for GYN patients. An institutional workflow was established for the clinical implementation of the dosimetric system. Action levels were proposed based on the measurement and system uncertainty for measurement deviations. From October 2018 to September 2019, a total of 75 measurements (48 fractions) were acquired from 14 patients who underwent HDR brachytherapy using either a multichannel cylinder, Venezia applicator, or Syed-Neblett template. The PSDs were placed in predetermined catheters/channels. A planning CT was acquired for treatment planning in Oncentra (Elekta, Version-4.5.2) TPS. The PSDs were contoured on the CT images, and the PSD D90% values were used as the expected doses for comparison with the measured doses. Results: The mean difference from patient measurements was −0.22% ± 5.98%, with 26% being the largest deviation from the expected value (Syed case). Large deviations were observed when detectors were placed in the area where dose rates were less than 1 cGy/s. Conclusions: The establishment of clinical workflow for the in vivo dosimetry for both the intracavitary and interstitial GYN HDR brachytherapy will potentially improve the safety of the patient treatment.
UR - http://www.scopus.com/inward/record.url?scp=85095875689&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095875689&partnerID=8YFLogxK
U2 - 10.1016/j.brachy.2020.09.010
DO - 10.1016/j.brachy.2020.09.010
M3 - Article
C2 - 33187822
AN - SCOPUS:85095875689
VL - 20
SP - 353
EP - 360
JO - Brachytherapy
JF - Brachytherapy
SN - 1538-4721
IS - 2
ER -